MyFinsight
Home
Blog
About
In-process research and
development, net of...
$88,785,938
Goodwill
$9,346,796
(0.00%↑ Y/Y)
Deposits
$38,062
(0.00%↑ Y/Y)
Inventory
$22,625,945
(31.48%↑ Y/Y)
Cash and cash
equivalents
$17,007,523
(179.31%↑ Y/Y)
Prepaid expenses
$3,011,660
(129.34%↑ Y/Y)
Accounts receivable, net
of allowances
$686,235
Total other assets
$98,170,796
(-3.93%↓ Y/Y)
Total current assets
$43,331,363
(76.06%↑ Y/Y)
Operating lease
right-of-use asset, net
$753,039
(-14.50%↓ Y/Y)
Total assets
$142,255,198
(11.42%↑ Y/Y)
Total liabilities and
equity
$142,255,198
(11.42%↑ Y/Y)
Total equity
$75,908,456
(12.36%↑ Y/Y)
Total liabilities
$66,346,742
(10.36%↑ Y/Y)
Total citius
pharmaceuticals, inc....
$66,613,132
(2.39%↑ Y/Y)
Non-controlling interest
$9,295,324
(271.46%↑ Y/Y)
Total current
liabilities
$51,649,351
(-0.37%↓ Y/Y)
Deferred tax liability
$7,696,443
(2.53%↑ Y/Y)
Notes payable, net of
deferred financing fees
$6,410,161
Operating lease liability
noncurrent
$590,787
(-22.97%↓ Y/Y)
Accumulated deficit
-$277,118,897
(-20.05%↓ Y/Y)
Additional paid-in capital
$343,704,577
(16.16%↑ Y/Y)
Accrued expenses
$25,913,962
(204.02%↑ Y/Y)
License payable
$15,650,000
(-44.89%↓ Y/Y)
Accounts payable
$8,037,899
(-20.37%↓ Y/Y)
Accrued compensation
$1,871,320
(-49.56%↓ Y/Y)
Operating lease liability
$176,170
(53.60%↑ Y/Y)
Common stock - 0.001 par
value 250,000,000...
$27,452
(89.65%↑ Y/Y)
Back
Back
Balance Sheet
Citius Pharmaceuticals, Inc. (CTXR)
Citius Pharmaceuticals, Inc. (CTXR)
source: myfinsight.com